|
Author:
Date:
2017-06-05
[Abstract] The main obstacle to eradicating HIV-1 from patients is post-integration latency (Finzi et al., 1999). Antiretroviral treatments target only actively replicating virus, while latent infections that have low or no transcriptional activity remain untreated (Sedaghat et al., 2007). To eliminate viral reservoirs, one strategy focuses on reversing HIV-1 latency via ‘shock and kill’ (Deeks, 2012). The basis of this strategy is to overcome the molecular mechanisms of HIV-1 latency by therapeutically inducing viral gene and protein expression under antiretroviral therapy and to cause selective cell death via the lytic properties of the virus, or the immune system now recognizing the infected cells. Recently, a number of studies have described the therapeutic potential of ...
[摘要] 消除HIV-1患者的主要障碍是后整合延迟（Finzi等人，1999）。抗逆转录病毒治疗仅针对主动复制病毒，而具有低转录活性或无转录活性的潜伏感染仍未得到治疗（Sedaghat等人，2007）。为了消除病毒性水库，一项战略重点是通过“休克和杀死”来逆转HIV-1潜伏期（Deeks，2012）。该策略的基础是通过在抗逆转录病毒治疗下通过治疗性诱导病毒基因和蛋白质表达来克服HIV-1潜伏期的分子机制，并通过病毒的溶解性质或现在识别感染细胞的免疫系统引起选择性细胞死亡。最近，许多研究已经描述了药物抑制人类溴结构域蛋白质的溴结构域和末端（BET）家族的成员的治疗潜力（Filippakopoulos等人，2010; Dawson等人＆ / em>，2011; Delmore等人，2011），其包括BRD2，BRB3，BRD4和BRDT。小分子BET抑制剂，例如JQ1（Filippakopoulos et al。，2010; Delmore等人，2011），I-BET（Nicodeme等人＆lt; / ...
|